Product
AB521
3 clinical trials
2 indications
Indication
Advanced Clear Cell Renal Cell CarcinomaIndication
Healthy ParticipantsClinical trial
A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors.Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A First-in-human, Participant and Investigator-blinded, Randomized, Placebo-controlled, Single-and Multiple-Ascending Dose Study With Drug-Drug Interaction, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521, in Healthy VolunteersStatus: Completed, Estimated PCD: 2023-02-17
Clinical trial
A Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Way Crossover, Pharmacokinetic Study to Evaluate the Relative Bioavailability of AB521 Tablet and Capsule Formulations and the Effect of Food on the Pharmacokinetics of the Tablet Formulation in Healthy Adult VolunteersStatus: Completed, Estimated PCD: 2023-10-27